Renovaro Biosciences has completed its merger with BioSymetrics.
The merger is aimed at strengthening Renovaro’s capabilities in biomarker discovery and expanding its AI-powered diagnostics platform. The integration of BioSymetrics' technologies will also introduce in vivo validation and additional drug discovery tools into Renovaro’s portfolio.
Central to BioSymetrics’ offering is its proprietary Elion platform. This advanced AI and machine learning system is designed to detect complex biological patterns that support the development of diagnostics and treatments. In addition, BioSymetrics’ Phenograph engine links human clinical data to therapeutic targets, aiding in biomarker identification, patient categorisation, and drug repurposing.
The company’s in vivo modelling and AI-powered machine vision systems allow for high-throughput phenotypic screening. These tools support detailed analysis of biological reactions and have resulted in the creation of a large database of behavioural and morphological data from preclinical research. This approach aims to speed up therapeutic development by combining computational predictions with experimental validation.
BioSymetrics has previously formed partnerships with industry leaders such as Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. With the integration of the Elion platform into Renovaro’s systems, the merged entity plans to enhance its efficiency in biomarker identification and shorten the time needed for drug development.
The combined expertise in oncology, neurology, and AI is expected to support the development of more targeted and effective treatments. Renovaro will now have access to tools that could improve patient stratification, predict treatment outcomes more accurately, and accelerate clinical applications.
This strategic merger reflects both companies’ shared focus on using AI and data to improve outcomes in precision medicine. The newly combined business will continue working towards faster, smarter therapeutic development with the aim of bringing more effective treatments to patients around the world.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!